The low molecular weight heparin market in North America is expected to grow from US$ 1,232.86 million in 2021 to US$ 1,963.46 million by 2028; it is estimated to grow at a CAGR of 6.9% from 2021 to 2028.
Anticoagulants prevent clotting of blood and the growth of existing blood clots in blood vessels. In recent years, the development of methods for the prevention, and pharmacological and surgical treatment of thrombosis have improved considerably. The LMWHs are being used in the treatment of antithrombotic diseases for the past two decades. Owing to the structural complexity of anticoagulants and the presence of impurities, their structural characterization requires advanced analytical techniques. The LMWH exhibits anticoagulant properties such as anti-tumor, anti-inflammatory, and anti-proliferative effects, which are useful in the treatment of pathologies such as nephrotic syndrome and Alzheimer's disease. The patents of LMWH's have now expired. However, the market potential for LMWH is growing due to the increasing use in several emerging countries owing to its uses, such as thromboprophylaxis, venous thromboembolism (VTE), and anticoagulation treatment during pregnancy. As a result, pharmaceutical companies in many countries are focused on producing generic LMWHs. Enoxaparin is the world's best-selling LMWH. Pharmaceutical companies are also conducting various research and development activities to manufacture enoxaparin biosimilar. This further leads to intense competition in the LMWH market. Pharmaceutical companies either produced biosimilars or renamed the generic versions of the branded LMWH. In particular, copies of enoxaparin are available mainly in North America, which is further anticipated to drive the market in North America.
North America is highly affected due to the COVID-19 pandemic. This led to increased demand for diagnosing and therapeutic devices in hospitals. The FDA has increased its efforts to provide healthcare to people and has imposed several guidelines for hospitals and medical device companies. Various companies also enhanced their research and development activities for diagnostics tests and therapeutic devices. Despite facing the ill effects of SARS and H1N1 outbreaks in the last few years, the severity of the COVID-19 pandemic made the situation more complicated for the healthcare sectors due to its mode of transmission. The ongoing pandemic is straining public health systems globally, interrupting and delaying critical healthcare procedures. As per the IRI data, demand for various dietary supplements grew after the onset of the COVID-19 pandemic in the US at unprecedented rates. The total supplement sales increased by 6% during the first week of March 2020.
North America Low Molecular Weight Heparin Market Revenue and Forecast to 2028 (US$ Million)
North America Low Molecular Weight Heparin Market Segmentation
North America Low Molecular Weight Heparin Market – By Product Type
- Enoxaparin
- Dalteparin
- Tinzaparin
- Fraxiparine
- Nadroparin
- Others
North America Low Molecular Weight Heparin Market – By Packaging
- Multi-Vials
- Prefilled Syringes
North America Low Molecular Weight Heparin Market – By Application
- Deep Vein Thrombosis
- Acute Coronary Syndrome (ACS)
- Pulmonary Embolism
- Others
North America Low Molecular Weight Heparin Market – By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
North America Low Molecular Weight Heparin Market– By Country
- US
- Canada
- Mexico
North America Low Molecular Weight Heparin Market-Companies Mentioned
- Abbott
- Aspen Holdings
- B. Braun Medical Inc.
- Dr. Reddy's Laboratories
- LEO Pharma A/S
- Novartis
- Pfizer Inc.
- Sanofi
- TEVA PHARMACEUTICAL INDUSTRIES LTD
North America Low Molecular Weight Heparin Market Strategic Insights
North America Low Molecular Weight Heparin Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 1,232.86 Million |
| Market Size by 2028 | US$ 1,963.46 Million |
| CAGR (2021 - 2028) | 6.9% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Product Type
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Low Molecular Weight Heparin Market Country and Regional Insights
